Defibrillators

...The profit was cut a further $26 million, or 2 cents per share, from other special charges, mostly from Guidant.Excluding such one-time items in both comparable periods, Boston Scientific said its first-quarter profit was $295 million, or 20 cents per share, down from $415 million, or 50 cents per share, in the year-ago period.Boston Scientific reported earnings after its shares closed up 11 cents, or nearly 0.7 percent, at $16.09 on the New York Stock Exchange.

The shares fell 42 cents, or 2.6 percent, to $15.67 in after-hours trading.First-quarter sales of Boston Scientific's Taxus drug-coated stent fell 26 percent to $468 million from $633 million a year ago.

Drug-coated stent sales have fallen off amid concerns that the devices may put patients at slightly higher risk for blood clots than older bare-metal stents.A study released in March created more trouble for stent makers by questioning whether the tiny mesh-metal devices are more effective than less-costly drug therapy at treating patients with clogged coronary arteries who don't f...

...Salt Lake Tribune - Texas Instruments' first quarter beats expectations despite 4 percent drop Home News Contents Past Editions Archives Nation & World Utah Weather Traffic Utah Politics Crime & Justice Polygamy LDS Education Photos Blogs RSS Columnists Sports Prep Sports College Sports Utah Jazz Real Salt Lake Utah Blaze Grizzlies Bees Golf Winter Sports Outdoors Columnists Blogs Game Matchups Live Odds Features Arts Faith Food Gardening Health At Home Outdoors The Mix Travel Columnists Blogs Entertainment Film-Finder Sundance Arts Dining Out Food Multimedia Television The Mix Columnists Blogs Crossword Business Personal Finance Real Estate Stocks Technology Tourism Opinion Editorials Commentaries Public Forum Letters Bagley Cartoons TribTalk Blogs Close-Up Davis County Holladay Midvale Salt Lake/Avenues Sandy/Draper Sugarhouse West/South Jordan West Valley Obituaries Classifieds Classifieds Homes Cars Jobs Thrifties Dogs All Classifieds Legal Notices Home Business More Sites Community News E-edition Elections Guide Fantasy Sports Fronteras Grocery Holiday Guide Hometown Values In Utah This Week Shopping Utah Journal of Commerce Utah Bride Guide Veterans Tribute Help Desk Contact Us FAQ Circulation Subscribe Advertising Info.

Place an ad Make a payment Ad rate cards More Business News Business GlanceBarclays, Bank of America announce they'll split ABNTech guru's startup company lands major GE contractStocks take a slide after closing in on mag...

...The profit was cut a further $26 million, or 2 cents per share, from other special charges, mostly from Guidant.Excluding such one-time items in both comparable periods, Boston Scientific said its first-quarter profit was $295 million, or 20 cents per share, down from $415 million, or 50 cents per share, in the year-ago period.Boston Scientific reported earnings after its shares closed up 11 cents, or nearly 0.7 percent, at $16.09 on the New York Stock Exchange.

The shares fell 42 cents, or 2.6 percent, to $15.67 in after-hours trading.First-quarter sales of Boston Scientific's Taxus drug-coated stent fell 26 percent to $468 million from $633 million a year ago.

Drug-coated stent sales have fallen off amid concerns that the devices may put patients at slightly higher risk for blood clots than older bare-metal stents.A study released in March created more trouble for stent makers by questioning whether the tiny mesh-metal devices are more effective than less-costly drug therapy at treating patients with clogged coronary arteries who don't f...